New Dermal Filler for Chin Correction and Augmentation
Launched by GALDERMA R&D · Nov 10, 2020
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • subject willing to comply with the requirements of the study
- • subject intent to receive treatment for augmentation and correction of retrusion in the chin region
- • subject with mild or moderate (grade 1 or 2) on the GCRS
- Exclusion Criteria:
- • subjects presenting with know allergy to HA (hyaluronic acid) filler or amide local anesthetics
- • subjects with any previous facial surgery below the nasal line or previous HA filler or collagen below the nasal line within 12 months
- • subjects in any other interventional clinical study within 30 days before baseline
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Burlington, Ontario, Canada
Toronto, Ontario, Canada
Woodbridge, Ontario, Canada
Westmount, Quebec, Canada
Patients applied
Trial Officials
Study Director
Study Director
Galderma R&D
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials